Aegerion price target raised to $52 from $41 at Deutsche Bank Deutsche Bank raised its price target for Aegerion after meeting with management and keeps a Buy rating on the stock. The firm believes the Juxtapid U.S. launch is already ahead of expectations.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.